An infant from rural South Australia is in a stable condition in hospital, after being diagnosed with invasive meningococcal disease identified as serotype B.
SA Health has identified multiple people who have been in contact with the case and two people have been directed to receive clearance antibiotics to prevent further transmission.
Meningococcal case breakdown:
| 2026 | 2025 | |
|---|---|---|
| Year-to-date count | 3 | 1 |
| Annual count | 3 | 15 |
| Deaths | 0 | 0 |
| Serogroup B | 3 | 13 |
| Serogroup W | 0 | 0 |
| Serogroup Y | 0 | 1 |
| Non-serogroupable | 0 | 1 |
Symptomsand signs of meningococcal disease can include headache, fever, vomiting, neckstiffness, and discomfort when looking at lights. A skin rash may occur, withtiny red or purple spots that soon spread and enlarge to look like freshbruises. At later stages of the illness, people may develop confusion andshock. In addition, young children may be fretful, difficult to wake and refuseto eat. They may have leg pain, cold hands and feet, and a high-pitched ormoaning cry. Children may also have pale, blotchy or abnormally coloured skin.
It is important to seek urgent medical attention if symptoms and/or signs of meningococcal disease develop as meningococcal disease can progress very rapidly and be life-threatening.
Vaccines are available to protect against a number of types of meningococcal disease. In South Australia, under national and state funded programs, the meningococcal B vaccine is available and free for infants at six weeks, four months, and 12 months and for adolescents in Year 10. The ACWY vaccine is available and free for infants at 12 months and in adolescents in Year 10.
As vaccines do not protect against all types of meningococcal disease, vaccinated people must still be alert for the symptoms of meningococcal disease.
Meningococcal health information has also been provided to the contacts in accordance with the Invasive Meningococcal DiseaseCommunicable Diseases Network Australia: National Guidelines for Public HealthUnits.
